ClinicalTrials.Veeva

Menu
The trial is taking place at:
C

Central Research Associates | Birmingham, AL

Veeva-enabled site

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (STRIDE-13)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Enrolling
Phase 3

Conditions

Pneumococcal Infection

Treatments

Biological: V116
Biological: PPSV23

Study type

Interventional

Funder types

Industry

Identifiers

NCT06177912
jRCT2031230559 (Registry Identifier)
V116-013 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children 2 through 17 years of age. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting invasive pneumococcal disease (IPD).

Enrollment

820 estimated patients

Sex

All

Ages

2 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Has a diagnosis and stable medical management (for at least 3 months) of one of the following risk conditions for pneumococcal disease: Diabetes mellitus, chronic compensated liver disease, chronic lung disease, chronic heart disease, or chronic kidney disease.
  • Has completed pneumococcal conjugate vaccine regimen (PCV7, PCV10, or PCV13) at least 8 weeks before study enrollment.

Exclusion criteria

  • Has previously received PPSV23 vaccine
  • Has a history of active hepatitis within 3 months before study vaccination
  • History of invasive pneumococcal disease within 3 years before study vaccination

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

820 participants in 2 patient groups

V116
Experimental group
Description:
Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1
Treatment:
Biological: V116
PPSV23
Active Comparator group
Description:
Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
Treatment:
Biological: PPSV23

Trial contacts and locations

90

Loading...

Central trial contact

Toll Free Number

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems